Echevarria C, et al. - Researchers assessed health and social costs at 90 days in patients admitted with a low-risk COPD exacerbation (ECOPD) (DECAF 0 or 1) recruited to Hospital at Home (HAH) or usual care (UC), to ultimately assess the safety as well as efficacy of DECAF score in the selection of HAH. Most patients preferred HAH selected by low-risk DECAF score and moreover, it was found to be safe, clinically effective as well as cost-effective. Selection was simpler and approximately twice as many patients were eligible, relative to earlier models. In association with the introduction of DECAF, a fall in UC length of stay was noted, without adverse outcome. This finding supported use of DECAF to direct early discharge.